JACOB BOLLINGER: Open Payments
NPI 1952944316 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$894 in 43 payments from 13 companies in 2025. Trend: 2023 $365 · 2024 $523 · 2025 $894
Food & beverage: $804Education: $90
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 11 | $280 |
| Amgen Inc. | 7 | $149 |
| Novo Nordisk Inc | 8 | $138 |
| PFIZER INC. | 3 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Dexcom, Inc. | 2 | $37 |
| Exact Sciences Corporation | 2 | $36 |
| Boston Scientific Corporation | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
Products named: MOUNJARO, Wegovy, REPATHA, OTEZLA, TRINTELLIX, ELIQUIS, Dexcom G6 Transmitter, Cologuard Collection Kit.
Industry payments across MD — which companies pay providers there.
